SG11201900128XA - Anti-il-22r antibodies - Google Patents

Anti-il-22r antibodies

Info

Publication number
SG11201900128XA
SG11201900128XA SG11201900128XA SG11201900128XA SG11201900128XA SG 11201900128X A SG11201900128X A SG 11201900128XA SG 11201900128X A SG11201900128X A SG 11201900128XA SG 11201900128X A SG11201900128X A SG 11201900128XA SG 11201900128X A SG11201900128X A SG 11201900128XA
Authority
SG
Singapore
Prior art keywords
international
argenx
bvba
zwijnaarde
building
Prior art date
Application number
SG11201900128XA
Other languages
English (en)
Inventor
Christophe Frederic Jerome Blanchetot
Birgitte Ursø
Tine Skak-Nielsen
Malene Bertelsen
Der Woning Sebastian Van
Michael Saunders
Haard Johannes Joseph Wilhelmus De
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of SG11201900128XA publication Critical patent/SG11201900128XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201900128XA 2016-07-15 2017-07-14 Anti-il-22r antibodies SG11201900128XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1612337.4A GB201612337D0 (en) 2016-07-15 2016-07-15 Ant-il-22r antibodies
PCT/EP2017/067923 WO2018011420A1 (fr) 2016-07-15 2017-07-14 Anticorps anti-il-22r

Publications (1)

Publication Number Publication Date
SG11201900128XA true SG11201900128XA (en) 2019-02-27

Family

ID=56890507

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900128XA SG11201900128XA (en) 2016-07-15 2017-07-14 Anti-il-22r antibodies

Country Status (27)

Country Link
US (4) US10696741B2 (fr)
EP (2) EP4023674A3 (fr)
JP (1) JP7163275B2 (fr)
KR (2) KR20230128137A (fr)
CN (1) CN109641966B (fr)
AU (1) AU2017296094B2 (fr)
BR (1) BR112019000788A2 (fr)
CA (1) CA3024370A1 (fr)
CY (1) CY1125041T1 (fr)
DK (1) DK3484921T3 (fr)
ES (1) ES2903412T3 (fr)
GB (1) GB201612337D0 (fr)
HR (1) HRP20220197T1 (fr)
HU (1) HUE057615T2 (fr)
IL (1) IL264262A (fr)
LT (1) LT3484921T (fr)
MX (1) MX2019000539A (fr)
MY (1) MY197821A (fr)
PL (1) PL3484921T3 (fr)
PT (1) PT3484921T (fr)
RS (1) RS62884B1 (fr)
RU (1) RU2758721C2 (fr)
SA (1) SA519400856B1 (fr)
SG (1) SG11201900128XA (fr)
SI (1) SI3484921T1 (fr)
UA (1) UA125585C2 (fr)
WO (1) WO2018011420A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
KR20210019464A (ko) * 2018-06-05 2021-02-22 바이오아트라, 인코퍼레이티드 항 il-22 항체, 항체 단편, 이의 면역접합체 및 이의 용도
CN110302363B (zh) * 2019-07-04 2020-10-09 北京大学第三医院（北京大学第三临床医学院） Il-22作为制备治疗pcos药物的应用及药物制剂
WO2023232789A1 (fr) 2022-06-03 2023-12-07 Leo Pharma A/S Formulation liquide d'anticorps il-22r

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
ATE475673T1 (de) * 2003-03-24 2010-08-15 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
ATE474856T1 (de) * 2004-10-22 2010-08-15 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
WO2007126439A2 (fr) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions et méthodes de traitement de maladies et troubles associés é la signalisation de la cytokine
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
UA105405C2 (ru) * 2009-11-19 2014-05-12 Мерк Сероно С.А. Гуманизированное антитело против человеческого il-22ra
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2791172B1 (fr) * 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Composés et méthodes de traitement de maladies inflammatoires
WO2014033252A1 (fr) 2012-08-31 2014-03-06 arGEN-X BV Procédé de production de molécules d'anticorps ayant une activité croisée interspécifique, intra-cible
US10093737B2 (en) * 2013-03-01 2018-10-09 Albert Einstein College Of Medicine, Inc. HHLA2 as a novel inhibitor of human immune system and uses thereof
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies

Also Published As

Publication number Publication date
JP2019528046A (ja) 2019-10-10
DK3484921T3 (da) 2022-02-07
US11447544B2 (en) 2022-09-20
RS62884B1 (sr) 2022-03-31
GB201612337D0 (en) 2016-08-31
SA519400856B1 (ar) 2022-10-25
SI3484921T1 (sl) 2022-02-28
PT3484921T (pt) 2022-01-26
KR20190026766A (ko) 2019-03-13
US20200157207A1 (en) 2020-05-21
CA3024370A1 (fr) 2018-01-18
CY1125041T1 (el) 2023-03-24
HRP20220197T1 (hr) 2022-04-29
WO2018011420A1 (fr) 2018-01-18
LT3484921T (lt) 2022-01-10
MX2019000539A (es) 2019-10-04
CN109641966A (zh) 2019-04-16
EP3484921B1 (fr) 2021-11-17
JP7163275B2 (ja) 2022-10-31
RU2019103991A (ru) 2020-08-17
HUE057615T2 (hu) 2022-05-28
PL3484921T3 (pl) 2022-03-28
UA125585C2 (uk) 2022-04-27
US20230088269A1 (en) 2023-03-23
CN109641966B (zh) 2022-08-23
EP4023674A2 (fr) 2022-07-06
AU2017296094B2 (en) 2024-02-01
RU2019103991A3 (fr) 2021-04-29
BR112019000788A2 (pt) 2019-07-02
US10696741B2 (en) 2020-06-30
KR20230128137A (ko) 2023-09-01
EP3484921A1 (fr) 2019-05-22
KR102571012B1 (ko) 2023-08-24
EP4023674A3 (fr) 2022-10-05
US20200216528A1 (en) 2020-07-09
ES2903412T3 (es) 2022-04-01
US20190127459A1 (en) 2019-05-02
IL264262A (en) 2019-02-28
MY197821A (en) 2023-07-18
RU2758721C2 (ru) 2021-11-01
AU2017296094A1 (en) 2018-12-13
US11261246B2 (en) 2022-03-01

Similar Documents

Publication Publication Date Title
SG11201810509PA (en) Anti-pd-l1 antibodies
SG11201909949XA (en) Targeted immunotolerance
SG11201811432WA (en) Rna for cancer therapy
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201808242UA (en) Methods for inhibiting angiogenesis in a subject in need thereof
SG11201811184UA (en) Lag -3 binding members
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201810179RA (en) Novel crispr enzymes and systems
SG11201906392WA (en) Nucleoside-modified rna for inducing an immune response against zika virus
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201900128XA (en) Anti-il-22r antibodies
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201806758VA (en) Vcn enhancer compositions and methods of using the same
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11202000055PA (en) Antibodies that modulate a biological activity expressed by a cell
SG11201811643TA (en) Compounds and methods for modulating rna function
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201903892UA (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof